Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211065 · ClinicalTrials.gov registry record · Phase 2
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
A Phase 2 study, sponsored by Rochester General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03211065: Completed Phase 2 study, sponsored by Rochester General Hospital.
NCT03211065 is a Phase 2 study that has completed, run by Rochester General Hospital. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03211065, a Phase 2 study, has completed, sponsored by Rochester General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.
Primary Outcome
How many antibiotics are prescribed in one year for any type of infection
Interventions
- DRUG 20% subcutaneous immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2019-11-01 |
| Phase | Phase 2 |
What the finished NCT03211065 record still lists
NCT03211065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which 20% subcutaneous immunoglobulin is the first listed.
NCT03211065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03211065 about?
NCT03211065 is a clinical study titled "Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig". To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal...
What is the current status of trial NCT03211065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-07-21. Estimated completion is 2019-11-01.
What interventions are being tested in trial NCT03211065?
The interventions under investigation include: 20% subcutaneous immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT03211065?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03211065's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI